Among the liver cancer chemotherapeutic drugs oxaliplatin and doxorubicin, ACLY can be acetylated by NAT10 at lysine 468, which confers resistance to chemotherapy in HCC cells and mouse xenografts. Here, NAT10 is linked to liver cancer.